Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
17.29
-1.13 (-6.13%)
Sep 26, 2024, 4:00 PM EDT - Market closed
Zenas BioPharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -54.76 | -37.12 | -119.28 |
| Depreciation & Amortization | 0.12 | 0.11 | 0.08 |
| Asset Writedown & Restructuring Costs | - | 10 | 1 |
| Stock-Based Compensation | 4.62 | 3.5 | 0.74 |
| Other Operating Activities | 1.77 | 1.03 | 43.85 |
| Change in Accounts Payable | 4.71 | -0.42 | 1.09 |
| Change in Other Net Operating Assets | 9.92 | -7.62 | 6.88 |
| Operating Cash Flow | -33.62 | -30.53 | -65.65 |
| Capital Expenditures | -0.07 | -0.02 | -0.2 |
| Sale (Purchase) of Intangibles | - | - | -2 |
| Investing Cash Flow | -0.07 | -0.02 | -2.2 |
| Long-Term Debt Issued | - | 20 | - |
| Net Debt Issued (Repaid) | 20 | 20 | - |
| Issuance of Common Stock | 0.22 | 0.12 | - |
| Financing Cash Flow | 197.18 | 20.12 | 59.39 |
| Foreign Exchange Rate Adjustments | -0.02 | 0.08 | -0.04 |
| Net Cash Flow | 163.47 | -10.35 | -8.5 |
| Free Cash Flow | -33.69 | -30.55 | -65.85 |
| Free Cash Flow Margin | -67.38% | -61.09% | - |
| Free Cash Flow Per Share | -2.50 | -2.30 | -5.08 |
| Levered Free Cash Flow | - | -17.64 | - |
| Unlevered Free Cash Flow | - | -17.64 | - |
| Change in Net Working Capital | - | 4.26 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.